Physician profile
Mary Crabtree
NPI 1700196425
$354.36
in general payments reported to CMS, 2019-2025
11 companies · $14.39 in 2025
The $14.39 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.50 · 2022: $23.53 · 2023: $106 · 2024: $197 · 2025: $14.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.48 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $64.27 | 2022-2023 | Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $57.61 | 2023-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $36.00 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2024 | |
| Astellas Pharma US INC | $20.09 | 2024 | Veozah |
| Abbvie INC. | $20.03 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2023 | |
| Lilly USA, LLC | $14.72 | 2024 | Mounjaro |
| Genentech USA, INC. | $13.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.07 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.